Jack A. Ragheb
About Jack A. Ragheb
Jack Ragheb is the Senior Vice President of Translational Science, known for his extensive background in immunology and his role as the Scientific Founder of JoMoCo Inc.
Jack Ragheb Company and Title
Jack Ragheb is the Senior Vice President, Translational Science. He has a significant background in both the pharmaceutical industry and government health agencies, with a focus on immunology and translational science.
Jack Ragheb Education and Expertise
Jack Ragheb graduated from Johns Hopkins University and the Johns Hopkins School of Medicine. He is a diplomate of the American Board of Allergy and Immunology, demonstrating a high level of expertise and certification in his field. Ragheb's broad research and clinical work have contributed to the fields of retrovirology, gene therapy, immune activation, therapeutic protein immunogenicity, and clinical trials in immune tolerance.
Jack Ragheb Background in Immunology and Translational Science
Jack Ragheb has accumulated extensive experience in immunology and translational science. He previously served as the Senior Medical Fellow for Immunology at Eli Lilly & Co. He also held the position of Chief Medical Research Officer in the Laboratory of Immunology at the Office of Biotechnology Products, CDER, USFDA. Furthermore, he acted as an Attending Physician on the Allergy-Immunology Service at the National Institute of Allergy and Infectious Diseases (NIAID).
Jack Ragheb Achievements and Scientific Contributions
Jack Ragheb is known for his contributions to medical research and healthcare. He worked as a Senior Clinical Investigator in the Laboratory of Immunology, National Eye Institute (NEI) at the National Institutes of Health (NIH). Ragheb has been involved in work and publications spanning retrovirology, gene therapy, immune activation, therapeutic protein immunogenicity, and clinical trials in immune tolerance. Additionally, he is the Scientific Founder of JoMoCo Inc., contributing to entrepreneurial ventures in the biotech sector.